The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | ENSURE: surveillance protocols after primary treatment of esophageal cancer
Jessie Elliott, FRCS, PhD, Trinity St. James’s Cancer Institute, Dublin, Ireland, discusses the results of the ENSURE study (NCT03461341), a multicenter study that looked at how surveillance practices for esophageal cancer differ across Europe and North America. The study found significant differences in how patients are followed up after treatment. While intensive surveillance with imaging and endoscopy did not appear to improve oncological outcomes in the overall patient group, the study did find some evidence that patients with early-stage disease or more favorable tumor biology benefited from an intensive approach. The study also found that intensive surveillance was associated with increased anxiety among patients. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
